Skip to ContentSkip to Navigation
About us Latest news News News articles

Influenza vaccination in primary and secondary immunodeficiencies

21 September 2011

PhD ceremony: Mr. S. van Assen, 16.15 uur, Aula Academiegebouw, Broerstraat 5, Groningen

Dissertation: Influenza vaccination in primary and secondary immunodeficiencies

Promotor(s): prof. C.G.M. Kallenberg

Faculty: Medical Sciences

 

Patients with immunodeficiencies are at increased risk of contracting common and/or opportunistic infections, that might be prevented or mitigated by vaccination. We investigated the humoral and cell-mediated immune (CMI) responses following influenza vaccination in patients with humoral primary immunodeficiencies (hPID), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)-patients treated with rituximab. In patients with hPID humoral responses following influenza vaccination were clearly hampered. Previous vaccination and treatment with intravenous immunoglobulin did not result in higher seroprotection rates. Antibody responses were also decreased in SLE-patients. A second influenza vaccination four weeks later only led to an additional increase in the influenza-specific antibody responses in not previously vaccinated SLE-patients. Influenza vaccination within four to eight weeks after administration of rituximab did not result in a humoral response in rituximab-induced B-cell depleted RA-patients. Six to 10 months following rituximab therapy an antibody response was found although it was still hampered. CMI responses following influenza vaccination were impaired in the hPID, SLE and rituximab-treated RA-patients. In SLE-patients reduced CMI responses were associated with the use of prednisone and/or azathioprine. In conclusion, the patients with primary and secondary immunodeficiencies we investigated demonstrated hampered humoral and CMI responses following influenza vaccination. We developed evidence- and expert-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases for the European League Against Rheumatism (EULAR).

 

Last modified:13 March 2020 01.09 a.m.
Share this Facebook LinkedIn
View this page in: Nederlands

More news

  • 06 June 2025

    India-Netherlands Hydrogen Valley Fellowship Programme announced

    To coincide with World Environment Day, 5 June 2025, the Indian Department of Science and Technology and the University of Groningen yesterday announced a Hydrogen Valley Fellowship Programme Partnership, allowing talented Indian scholars working on...

  • 28 May 2025

    Gaan avondmensen cognitief sneller achteruit dan ochtendmensen?

    Wie ’s avonds opleeft en laat naar bed gaat, heeft een grotere kans op cognitieve achteruitgang dan een ochtendmens, blijkt uit UMCG-onderzoek.

  • 27 May 2025

    An adventure in the brain

    In the exhibition Brainstorm in the University Mueseum, Iris Sommer and two other brain researchers from Groningen explain the gut-brain connection, how it was discovered that the brain does what it does, and how games motivate you to perform...